Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.